Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk

Overview

Journal J Am Coll Cardiol

Specialty Cardiology & Vascular Diseases

Date 2022 Feb 18

PMID 35177190

Authors

Mark Trinder

Kaavya Paruchuri

Sara Haidermota

Rachel Bernardo

Seyedeh Maryam Zekavat

Thomas Gilliland

James Januzzi Jr

Pradeep Natarajan

Affiliations

Soon will be listed here.

Abstract

Background: When indicated, guidelines recommend measurement of lipoprotein(a) for cardiovascular risk assessment. However, temporal variability in lipoprotein(a) is not well understood, and it is unclear if repeat testing may help refine risk prediction of coronary artery disease (CAD).

Objectives: The authors examined the stability of repeat lipoprotein(a) measurements and the association between instability in lipoprotein(a) molar concentration with incident CAD.

Methods: The authors assessed the correlation between baseline and first follow-up measurements of lipoprotein(a) in the UK Biobank (n = 16,017 unrelated individuals). The association between change in lipoprotein(a) molar concentration and incident CAD was assessed among 15,432 participants using Cox proportional hazards models.

Results: Baseline and follow-up lipoprotein(a) molar concentration were significantly correlated over a median of 4.42 years (IQR: 3.69-4.93 years; Spearman rho = 0.96; P < 0.0001). The correlation between baseline and follow-up lipoprotein(a) molar concentration were stable across time between measurements of <3 (rho = 0.96), 3-4 (rho = 0.97), 4-5 (rho = 0.96), and >5 years (rho = 0.96). Although there were negligible-to-modest associations between statin use and changes in lipoprotein(a) molar concentration, statin usage was associated with a significant increase in lipoprotein(a) among individuals with baseline levels ≥70 nmol/L. Follow-up lipoprotein(a) molar concentration was significantly associated with risk of incident CAD (HR per 120 nmol/L: 1.32 [95% CI: 1.16-1.50]; P = 0.0002). However, the delta between follow-up and baseline lipoprotein(a) molar concentration was not significantly associated with incident CAD independent of follow-up lipoprotein(a) (P = 0.98).

Conclusions: These findings suggest that, in the absence of therapies substantially altering lipoprotein(a), a single accurate measurement of lipoprotein(a) molar concentration is an efficient method to inform CAD risk.

Citing Articles

Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease.

Doherty S, Hernandez S, Rikhi R, Mirzai S, De Los Reyes C, McIntosh S Curr Cardiovasc Risk Rep. 2025; 19(1):8.

PMID: 39980866 PMC: 11836235. DOI: 10.1007/s12170-025-00760-1.

Persistent lipoprotein(a) exposure and its association with clinical outcomes after acute myocardial infarction: a longitudinal cohort study.

Wang Z, Tang J, Shi Q, Fang L, Liu N, Zhang J Ann Med. 2025; 57(1):2454975.

PMID: 39898960 PMC: 11792142. DOI: 10.1080/07853890.2025.2454975.

Lipoprotein(a), high-sensitivity c-reactive protein, homocysteine and cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis.

Nomura S, Bhatia H, Garg P, Karger A, Guan W, Cao J Am J Prev Cardiol. 2025; 21():100903.

PMID: 39802678 PMC: 11722194. DOI: 10.1016/j.ajpc.2024.100903.

Lipoprotein (a) is not associated with thrombus burden derived from CT pulmonary angiography in patients with acute pulmonary embolism.

Gressenberger P, Posch F, Adelsmayr G, Nagy E, Kaufmann-Buhler A, Steiner J Sci Rep. 2024; 14(1):25962.

PMID: 39472600 PMC: 11522666. DOI: 10.1038/s41598-024-77669-z.

Lipoprotein(a) and the atherosclerotic burden - Should we wait for clinical trial evidence before taking action?.

Fichtner I, Macchi C, Rizzuto A, Carugo S, Corsini A, Ruscica M Atheroscler Plus. 2024; 58:16-23.

PMID: 39435317 PMC: 11492331. DOI: 10.1016/j.athplu.2024.09.004.

References

Willeit P, Ridker P, Nestel P, Simes J, Tonkin A, Pedersen T . Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018; 392(10155):1311-1320. DOI: 10.1016/S0140-6736(18)31652-0. View

Trinder M, DeCastro M, Azizi H, Cermakova L, Jackson L, Frohlich J . Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia. J Am Coll Cardiol. 2020; 75(21):2682-2693. DOI: 10.1016/j.jacc.2020.03.065. View

Marcovina S, Albers J, Scanu A, Kennedy H, Giaculli F, Berg K . Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem. 2000; 46(12):1956-67. View

Pare G, Caku A, McQueen M, Anand S, Enas E, Clarke R . Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. Circulation. 2019; 139(12):1472-1482. DOI: 10.1161/CIRCULATIONAHA.118.034311. View

Szarek M, Bittner V, Aylward P, Baccara-Dinet M, Bhatt D, Diaz R . Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020; 41(44):4245-4255. PMC: 7724642. DOI: 10.1093/eurheartj/ehaa649. View

Larsson S, Gill D, Mason A, Jiang T, Back M, Butterworth A . Lipoprotein(a) in Alzheimer, Atherosclerotic, Cerebrovascular, Thrombotic, and Valvular Disease: Mendelian Randomization Investigation. Circulation. 2020; 141(22):1826-1828. PMC: 7614586. DOI: 10.1161/CIRCULATIONAHA.120.045826. View

Marcovina S, Albers J . Lipoprotein (a) measurements for clinical application. J Lipid Res. 2015; 57(4):526-37. PMC: 4808779. DOI: 10.1194/jlr.R061648. View

Kamstrup P, Nordestgaard B . Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population. JACC Heart Fail. 2015; 4(1):78-87. DOI: 10.1016/j.jchf.2015.08.006. View

Khera A, Won H, Peloso G, Lawson K, Bartz T, Deng X . Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol. 2016; 67(22):2578-89. PMC: 5405769. DOI: 10.1016/j.jacc.2016.03.520. View

10.

Marcovina S, Viney N, Hughes S, Xia S, Witztum J, Tsimikas S . Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a) and IONIS-APO(a)-L antisense oligonucleotide clinical trials. J Clin Lipidol. 2017; 12(1):122-129.e2. DOI: 10.1016/j.jacl.2017.10.024. View

11.

Emdin C, Khera A, Natarajan P, Klarin D, Won H, Peloso G . Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. J Am Coll Cardiol. 2016; 68(25):2761-2772. PMC: 5328146. DOI: 10.1016/j.jacc.2016.10.033. View

12.

Ference B, Yoo W, Alesh I, Mahajan N, Mirowska K, Mewada A . Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012; 60(25):2631-9. DOI: 10.1016/j.jacc.2012.09.017. View

13.

Nordestgaard B, Chapman M, Humphries S, Ginsberg H, Masana L, Descamps O . Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34(45):3478-90a. PMC: 3844152. DOI: 10.1093/eurheartj/eht273. View

14.

Tsimikas S . A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017; 69(6):692-711. DOI: 10.1016/j.jacc.2016.11.042. View

15.

Luirink I, Wiegman A, Kusters D, Hof M, Groothoff J, de Groot E . 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med. 2019; 381(16):1547-1556. DOI: 10.1056/NEJMoa1816454. View

16.

Burgess S, Ference B, Staley J, Freitag D, Mason A, Nielsen S . Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiol. 2018; 3(7):619-627. PMC: 6481553. DOI: 10.1001/jamacardio.2018.1470. View

17.

Domanski M, Tian X, Wu C, Reis J, Dey A, Gu Y . Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk. J Am Coll Cardiol. 2020; 76(13):1507-1516. DOI: 10.1016/j.jacc.2020.07.059. View

18.

Madsen C, Kamstrup P, Langsted A, Varbo A, Nordestgaard B . Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study. Arterioscler Thromb Vasc Biol. 2019; 40(1):255-266. DOI: 10.1161/ATVBAHA.119.312951. View

19.

Zekavat S, Ruotsalainen S, Handsaker R, Alver M, Bloom J, Poterba T . Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries. Nat Commun. 2018; 9(1):2606. PMC: 6031652. DOI: 10.1038/s41467-018-04668-w. View

20.

Lin J, Reilly M, Terembula K, Wilson F . Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria. PLoS One. 2014; 9(12):e114397. PMC: 4260843. DOI: 10.1371/journal.pone.0114397. View